Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Autor: Lin, Simeng, Kennedy, Nicholas A, Saifuddin, Aamir, Sandoval, Diana Mu��oz, Reynolds, Catherine J, Seoane, Rocio Castro, Kottoor, Sherine H, Pieper, Franziska P, Lin, Kai-Min, Butler, David K, Chanchlani, Neil, Nice, Rachel, Chee, Desmond, Bewshea, Claire, Janjua, Malik, McDonald, Timothy J, Sebastian, Shaji, Alexander, James L, Constable, Laura, Lee, James C, Murray, Charles D, Hart, Ailsa L, Irving, Peter M, Jones, Gareth-Rhys, Kok, Klaartje B, Lamb, Christopher A, Lees, Charlie W, Altmann, Daniel M, Boyton, Rosemary J, Goodhand, James R, Powell, Nick, Ahmad, Tariq, CLARITY IBD Study

Publikováno v: Nature Communications, 13, 1, pp. 1379
Nature Communications, 13, 1379
2022, ' Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab ', Nature Communications, vol. 13, no. 1, 1379, pp. 1379 . https://doi.org/10.1038/s41467-022-28517-z

Funder: Royal Devon and Exeter NHS Foundation Trust (Royal Devon & Exeter NHS Foundation Trust); doi: https://doi.org/10.13039/100009745
Funder: Roche (F. Hoffmann-La Roche Ltd); doi: https://doi.org/10.13039/100004337
Funder: Celltrion Hea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9ab1e6b1afed86c7cea0a09ae909d5c
https://doi.org/10.1038/s41467-022-28517-z

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

Autor: Kennedy, Nicholas A, Goodhand, James R, Bewshea, Claire, Nice, Rachel, Chee, Desmond, Lin, Simeng, Chanchlani, Neil, Butterworth, Jeffrey, Cooney, Rachel, Croft, Nicholas M, Hart, Ailsa L, Irving, Peter M, Kok, Klaartje B, Lamb, Christopher A, Limdi, Jimmy K, Macdonald, Jonathan, McGovern, Dermot Pb, Mehta, Shameer J, Murray, Charles D, Patel, Kamal V, Pollok, Richard Cg, Raine, Timothy, Russell, Richard K, Selinger, Christian P, Smith, Philip J, Bowden, Jack, McDonald, Timothy J, Lees, Charlie W, Sebastian, Shaji, Powell, Nicholas, Ahmad, Tariq, Contributors To The CLARITY IBD Study

Publikováno v: 2021, ' Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab ', Gut, vol. 70, no. 5, pp. 865-875 . https://doi.org/10.1136/gutjnl-2021-324388
Gut

ObjectiveAntitumour necrosis factor (anti-TNF) drugs impair protective immunity following pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious respiratory infections. We sought to determine whether infliximab-treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b6e01dd054652cb9b8697520d2d594a
https://hdl.handle.net/20.500.11820/1bfd49d0-2ff9-4251-9b80-3c64409dface

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.